Found 116 clinical trials
A Study to Evaluate INSTILADRIN® in Patients With High Grade, Bacillus Calmette-Guerin (BCG) Unresponsive NMIBC- Non muscle invasive bladder cancer
A Study to Evaluate INSTILADRIN® in Patients With High Grade, Bacillus Calmette-Guerin (BCG) Unresponsive NMIBC- Non muscle invasive bladder cancer
- 142 views
- 08 Nov, 2020
- 1 location
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
The purpose of this study is to assess the antitumor efficacy and safety of perioperative enfortumab vedotin (EV) plus pembrolizumab and radical cystectomy (RC) + pelvic lymph node dissection (PLND) compared with the current standard of care (neoadjuvant chemotherapy [gemcitabine plus cisplatin] and RC + PLND) for participants with MIBC …
- 0 views
- 14 Jun, 2021
- 33 locations
Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC
Muscle-Invasive Bladder Cancer
- 147 views
- 03 Jun, 2021
- 263 locations
Study of CG0070 Given in Patients With Non-Muscle Invasive Bladder Cancer Unresponsive to Bacillus-Calmette-Guerin
To evaluate the activity of intravesical (IVE) administration of CG0070 in patients with tissue pathology confirmed non-muscular invasive bladder cancer (NMIBC) who have Bacillus-Calmette-Guerin
- 0 views
- 22 May, 2021
- 32 locations
Study of Sasanlimab (PF-06801591) in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-Risk Non-Muscle Invasive Bladder Cancer
maintenance periods) is superior to BCG alone (induction and maintenance periods) in prolonging event free survival (EFS) in participants with high-risk nave non-muscle invasive bladder cancer (NMIBC) and to
- 10 views
- 09 Jun, 2021
- 208 locations
NORTH-REG Dwell-Time Study
Previous studies show that the majority NMIBC patients experience side effects to BCG and therefore terminate the instillations before completing all planned instillations. This will increase their risk of recurrence and potential cystectomy. The purpose of this study is to investigate if NMIBC patients who experience severe side effects to …
- 0 views
- 14 Feb, 2021
- 11 locations
Radiogenomics of Muscle Invasive Bladder Cancer
patients with muscle invasive bladder cancer.
- 0 views
- 07 Apr, 2021
- 1 location
Omega-3 Polyunsaturated Fatty Acids and Non-Muscle Invasive Bladder Cancer
The investigators hypothesize that omega-3 polyunsaturated fatty acids (n-3 PUFAs) might have a role in prevention of the recurrence of non-muscle invasive bladder cancer (NMIBC). The
- 0 views
- 28 Jan, 2021
- 1 location
Intravesical Ty21a for the Treatment of Patients With Non-muscle-invasive Bladder Cancer (NMIBC)
record. In this phase I trial we will be testing the safety of intravesical administration of Ty21a and its effect on bladder immunity in non-muscle invasive bladder cancer (NMIBC) patients, for whom
- 0 views
- 09 May, 2021
- 1 location
Low Energy Shock Wave Therapy and Non-Muscle Invasive Bladder Cancer
The investigators hypothesize that low energy shock wave therapy (LESW) might induce damage to the tumor tissues of non-muscle invasive bladder cancer (NMIBC), so they could be ablated and
- 0 views
- 27 Jan, 2021
- 1 location